Issue brief | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Issue brief | 26 March 2026 EthiopiaNigeriaSouth Sudan Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights
Interview | 24 March 2026 How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience
Letter | 16 March 2026 European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all
Press release | 05 March 2026 DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance
Technical brief | 09 February 2026 Ensuring Collective Efforts Deliver Equitable Access Through the WHO PABS System
Statement | 16 December 2025 Governments must take concrete actions to ensure equitable access to medical tools for noncommunicable diseases and mental health conditions
Issue brief | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Issue brief | 26 March 2026 EthiopiaNigeriaSouth Sudan Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights
Press release | 24 March 2026 MSF demands sustained investments and political will to end neglect of children with tuberculosis
Interview | 24 March 2026 How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience
Letter | 16 March 2026 European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all
Press release | 05 March 2026 DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance
Technical brief | 09 February 2026 Ensuring Collective Efforts Deliver Equitable Access Through the WHO PABS System
Statement | 16 December 2025 Governments must take concrete actions to ensure equitable access to medical tools for noncommunicable diseases and mental health conditions
Issue brief | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Issue brief | 26 March 2026 EthiopiaNigeriaSouth Sudan Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights
Press release | 24 March 2026 MSF demands sustained investments and political will to end neglect of children with tuberculosis
Interview | 24 March 2026 How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience
Letter | 16 March 2026 European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all
Press release | 05 March 2026 DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance
Statement | 16 December 2025 Governments must take concrete actions to ensure equitable access to medical tools for noncommunicable diseases and mental health conditions
Issue brief | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Issue brief | 26 March 2026 EthiopiaNigeriaSouth Sudan Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights
Press release | 24 March 2026 MSF demands sustained investments and political will to end neglect of children with tuberculosis
Interview | 24 March 2026 How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience
Letter | 16 March 2026 European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all
Press release | 05 March 2026 DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance
Technical brief | 09 February 2026 Ensuring Collective Efforts Deliver Equitable Access Through the WHO PABS System
Photo credit: Jinane Saad/MSF Press release Press release | 02 December 2025 Diabetes MSF responds to Novo Nordisk’s discontinuation of key insulin products in EU/EEA 2 min
UN Photo/Christopher Black Statement Statement | 01 December 2025 Pandemic preparedness MSF Statement at IGWG4 2 min
Photo Credit: Isaac Buay/MSF Feature story Feature story | 27 November 2025 Diabetes AfricaSouth Sudan How insulin pens are changing lives in South Sudan’s remote villages
Video Video | 20 November 2025 Antimicrobial resistance Discussion: Antimicrobial resistance in conflict-affected settings 2 min
19 November 2025 Intellectual property and trade CanadaUnited States of America MSF urges reform of United States-Mexico-Canada Agreement's (USMCA) pharmaceutical intellectual property provisions to safeguard public health